Mei Ri Jing Ji Xin Wen·2025-08-25 10:58Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Baike Biological, received the drug registration certificate for a nasal spray influenza live attenuated vaccine from the National Medical Products Administration [1] Group 1: Product Details - The vaccine is a nasal formulation with a specification of 0.2ml per dose [1] - It is intended for use in individuals aged 3 to 17 years [1] Group 2: Business Impact - The approval is expected to facilitate the promotion and use of Baike Biological's influenza vaccine, optimizing the company's product structure [1] - This development is anticipated to further enhance the company's core competitiveness [1] Group 3: Market Considerations - There is uncertainty regarding the timeline for the vaccine's market launch and sales [1]